Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03532893
Other study ID # 2017YFC1309500-1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 3, 2018
Est. completion date October 9, 2021

Study information

Verified date March 2022
Source Peking University First Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multi-center, prospective, cohort study. A total of 10,000 people aged 40~75 without lung disease will be recruited and followed for 3 years. By measure the rate of decline in forced expiratory volume at one second(FEV1) and baseline inflammatory biomarkers in exhaled breath condensate and peripheral blood, we aim to explore the predictive model for chronic obstructive pulmonary disease(COPD) in China.


Description:

This is a multi-center, prospective, cohort study. A total of 10,000 subjects aged 40~75 without history of lung disease will be recruited and followed for 3 years. The Department of Respiratory and Critical Care of Peking University First Hospital is responsible for this research. Other 9 units participating in the study, include the The Second Hospital of Hebei Medical University, Henan Provincial People's Hospital, The Second Hospital of Jilin University, The First Affiliated Hospital of Xi'an Jiaotong University, Shandong Provincial Hospital Affiliated to Shandong University,Shanxi Dayi Hospital, Tianjin Medical University General Hospital, The Affiliated Hospital of Inner Mongolia Medical University,The First Hospital of Qinhuangdao. Some questionnaire such as St George's Respiratory Questionnaire (SGRQ), income class, educational level, comorbidity, smoking habit and biomass smoke exposure history will be collected. The baseline level of Interleukin 6 (IL-6), high-sensitivity C-reactive Protein (hs-CRP), microRNAs-23a (miR-23a) in peripheral blood and pH value in exhaled breath condensate (EBC) will be measured, lung spirometry will be tested in the first, second and fourth years. Primary outcome is the incidence of COPD, multivariate regression analysis will be used to establish the predictive model for COPD in China. The study protocol has been approved by the Peking University First Hospital Institutional Review Board (IRB) (2018-31). Any protocol modifications will be submitted for the IRB review and approval.


Recruitment information / eligibility

Status Completed
Enrollment 10385
Est. completion date October 9, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: 1. aged at 40-75 years old; 2. FEV1/FVC>70% after inhaled bronchodilator 3. have willing to participate in this study, follow the research program and have the ability to sign the informed consent; 4. lived in a community for more than 1 years and has no plans to move out in the next 4 years 5. can be contacted Exclusion Criteria: 1. history of asthma, COPD, lung cancer, active pulmonary tuberculosis, bronchiectasis, diffuse lung disease (interstitial pneumonia, pulmonary sarcoidosis, occupational lung disease, sarcoidosis et al) and pleural disease; 2. history of lobectomy and / or lung transplantation; 3. predicted life expectancy less than 3 years; 4. history of severe psychiatric illnesses, mental disorders, neurological disorders, malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic kidney disease; 5. Alcoholism, drug abuse or abuse of toxic solvents; 6. Cannot finish long term follow-up or poor compliance; 7. Do not provide consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40~75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.

Locations

Country Name City State
China Peking University First Hospital Beijing Beijing
China The Second Hospital of Jilin University Changchun Jilin
China The Affiliated Hospital of Inner Mongolia Medical University Hohhot Inner Mongolia
China Shandong Provincial Hospital Affiliated to Shandong University Jinan Shandong
China The First Hospital of Qinhuangdao Qinhuangdao Hebei
China The Second Hospital of Hebei Medical University Shijiazhuang Hebei
China The First Affiliated Hospital of Shanxi Medical University Taiyuan Shanxi
China Tianjin Medical University General Hospital Tianjin Tianjin
China The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shanxi
China Henan Provincial People's Hospital Zhengzhou Henan

Sponsors (10)

Lead Sponsor Collaborator
Peking University First Hospital First Affiliated Hospital Xi'an Jiaotong University, Henan Provincial People's Hospital, Second Hospital of Jilin University, Shandong Provincial Hospital, Shanxi Dayi Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The First Hospital of Qinhuangdao, The Second Hospital of Hebei Medical University, Tianjin Medical University General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of COPD in the second and fourth year and the association between incidence of COPD and rapid decline of FEV1. FEV1/FVC(forced vital capacity)<70% (after bronchial dilation test);Detect the decline of FEV1(%)by Vitalograph COPD6. 4 years
Secondary The association between incidence of COPD and the air pollution level in different provinces in China. Record data of air pollution in different provinces in China from the environmental monitoring website. And analyze the correlation between the COPD incidence and air pollution level. 4 years
Secondary The association between incidence of COPD and different comorbidity condition, such as metabolic syndrome, cardiovascular disease. Record comorbidity condition data of human subjects, and then analyze the correlation between the COPD incidence and different comorbidity condition. 4 years
Secondary The mean decline rate of FEV1 Monitor pulmonary function decline in the second and the fourth year, then calculate the mean decline value. 4 years
Secondary The association between decline rate of FEV1 and air pollution level Record data of air pollution in different provinces in China from the environmental monitoring website. And analyze the correlation between the decline rate of FEV1 and air pollution level. 4 years
Secondary The correlation between the incidence of COPD and serum IL-6 level. Detect the serum IL-6 levels(ng/L), then analyze the correlation between the IL-6 levels and COPD incidence. 4 years
Secondary The correlation between the incidence of COPD and serum hs-CRP level. Detect the serum hs-CRP levels(ng/L), then analyze the correlation between the hs-CRP levels and COPD incidence. 4 years
Secondary The association between the pH value of EBC and COPD incidence. Detect the EBC pH value, then analyze the correlation between the EBC pH value and COPD incidence. 4 years
Secondary The association between serum miR-23a level and COPD incidence. Detect the serum miR-23a level, then analyze the correlation between serum miR-23a level and COPD incidence. 4 years
Secondary The association between incidence of COPD and other factors. The association between incidence of COPD and other factors (smoking habit, biomass exposure history, eating habit and incoming class).The incidence of COPD in the second and fourth year and the association between incidence of COPD and other factors (smoking habit(has or does not, if has: accumulative total smoking amount), biomass exposure history(yes or no), eating habit(light or greasy) and incoming class(family income per capita >¥4500, or not)). 4 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A